Drugs / BMS-275183
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT00332748 | Dec 2006 → Dec 2007 | cancer | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 1 | NCT00326131 | Apr 2006 → Mar 2007 | cancer | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 1 | NCT00207025 | Oct 2004 → Feb 2007 | neoplasm | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00103831 | ? → May 2005 | non-small cell lung carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00359450 | Jul 2006 → Mar 2007 | non-small cell lung carcinoma | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 2 | NCT00099879 | ? → Mar 2006 | non-small cell lung carcinoma | Bristol-Myers Squibb | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-275183 | “Effect of Esomeprazole on the Pharmacokinetics of BMS-275183 in Patients With Advanced Malignancies” NCT00332748 ↗5“single dose of BMS-275183 (labeled with radioactive carbon)” NCT00326131 ↗ “Phase I Alimta Combination With BMS-275183 (Oral Taxane)” NCT00103831 ↗ |
| Modality | Small molecule | “BMS-275183 (oral taxane)” NCT00359450 ↗ |
| Route | Oral | “Oral Taxane” NCT00103831 ↗ |